← Back to Search

Pulse Field Ablation

Pulse Field Ablation for Atrial Fibrillation (AdmIRE Trial)

N/A
Waitlist Available
Research Sponsored by Biosense Webster, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 - 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new method to treat patients with irregular heartbeats who haven't improved with drugs. The treatment works by stopping abnormal signals in the heart.

Who is the study for?
This trial is for individuals who have symptomatic paroxysmal atrial fibrillation, have had at least one documented AF episode in the past year, and failed at least one antiarrhythmic drug. It's not for those with persistent AF, previous ablations for AF, severe heart conditions like unstable angina or severe mitral regurgitation, or women who are pregnant.
What is being tested?
The trial tests the VARIPULSE™ Catheter with TRUPULSE™ Generator system's safety and effectiveness in isolating pulmonary veins to treat atrial fibrillation over a period of 12 months.
What are the potential side effects?
Potential side effects may include complications related to heart rhythm disturbances, issues from catheter insertion such as bleeding or infection, adverse reactions to anesthesia used during the procedure, and possible damage to surrounding structures in the heart.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 - 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 - 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Freedom of arrhythmia recurrence
Incidence of early onset Primary Adverse Events
Secondary study objectives
QOL Improvement

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment GroupExperimental Treatment1 Intervention
PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pulse Field Ablation
2022
N/A
~370

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Atrial Fibrillation (AF) include antiarrhythmic drugs, electrical cardioversion, and catheter ablation. Antiarrhythmic drugs work by altering the electrical signals in the heart to maintain a normal rhythm. Electrical cardioversion uses controlled electric shocks to reset the heart's rhythm. Catheter ablation, particularly pulmonary vein isolation (PVI), targets the areas of the heart where erratic electrical signals originate, using energy sources like radiofrequency or cryotherapy to create scar tissue that blocks these signals. The VARIPULSE™ Catheter with TRUPULSE™ Generator is an example of a PVI treatment that uses energy delivery to achieve this isolation. These treatments are crucial for AF patients as they help restore and maintain normal heart rhythm, reduce symptoms, and prevent complications such as stroke.

Find a Location

Who is running the clinical trial?

Biosense Webster, Inc.Lead Sponsor
126 Previous Clinical Trials
36,701 Total Patients Enrolled
85 Trials studying Atrial Fibrillation
28,618 Patients Enrolled for Atrial Fibrillation
Biosense Webster Inc. Clinical TrialStudy DirectorBiosense Webster, Inc.
1 Previous Clinical Trials
250 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
250 Patients Enrolled for Atrial Fibrillation

Media Library

VARIPULSE™ Catheter (Pulse Field Ablation) Clinical Trial Eligibility Overview. Trial Name: NCT05293639 — N/A
Atrial Fibrillation Research Study Groups: Treatment Group
Atrial Fibrillation Clinical Trial 2023: VARIPULSE™ Catheter Highlights & Side Effects. Trial Name: NCT05293639 — N/A
VARIPULSE™ Catheter (Pulse Field Ablation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05293639 — N/A
Atrial Fibrillation Patient Testimony for trial: Trial Name: NCT05293639 — N/A
~99 spots leftby Dec 2025